Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1999 | 1 |
2000 | 1 |
2005 | 1 |
2007 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
Curr Med Res Opin. 2005 Apr;21(4):517-26. doi: 10.1185/030079905x38196.
Curr Med Res Opin. 2005.
PMID: 15899100
Clinical Trial.
The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors.
Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezèau L, Carroll F, Pin JP, Cambria A, Vranesic I, Flor PJ, Gasparini F, Kuhn R.
Pagano A, et al. Among authors: litschig s.
J Biol Chem. 2000 Oct 27;275(43):33750-8. doi: 10.1074/jbc.M006230200.
J Biol Chem. 2000.
PMID: 10934211
Free article.
Item in Clipboard
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, Litschig S, Krammer G, Tate GA.
Willburger RE, et al. Among authors: litschig s.
Rheumatology (Oxford). 2007 Jul;46(7):1126-32. doi: 10.1093/rheumatology/kem090. Epub 2007 May 3.
Rheumatology (Oxford). 2007.
PMID: 17478464
Clinical Trial.
Item in Clipboard
CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.
Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R.
Litschig S, et al.
Mol Pharmacol. 1999 Mar;55(3):453-61.
Mol Pharmacol. 1999.
PMID: 10051528
Item in Clipboard
Cite
Cite